Full interview: ANGLE aiming for FDA approval of Parsortix in third quarter

ANGLE (LON:AGL) CEO Andrew Newland is confident that his company will receive regulatory clearance for its innovative Parsortix cancer test by the third quarter 2020 following a successful meeting with the US Food and Drug Administration (FDA).

Newland explains why that meeting was particularly important and how gratifying it was to see ANGLE catching the eye of significant investors at the recent JP Morgan Healthcare Conference in San Francisco.

Parsortix is a blood test designed to help doctors detect signs of cancer at an early stage, offering a less invasive alternative to tissue biopsies currently used in hospitals.

ANGLE said it is aiming to file its De Novo submission in the first quarter of 2020, with the prospect of regulatory clearance by the third quarter.

Quick facts: ANGLE PLC

Price: 40.5 GBX

Market: AIM
Market Cap: £87.24 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...


ANGLE completes FDA submission for Parsortix system for metastatic breast cancer

ANGLE PLC's (LON:AGL, OTCQX:ANPCY) Andrew Newland talks to Proactive's Katie Pilbeam after announcing the completion of their submission to the FDA for its Parsortix PC1 liquid biopsy for use in women with metastatic breast cancer (MBC). Newland calls the announcement 'a massive day' after...

on 28/9/20

2 min read